Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays
about
Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancersEmerging blood-based biomarkers for detection of gastric cancerA1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III.Pilot study of the application of magnetic bead protein profiling to the study of biomarkers in addiction research.Identification of apolipoprotein C-I as a potential Wilms' tumor marker after excluding inflammatory factorsMapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles.Clinical peptidomic analysis by a one-step direct transfer technology: its potential utility for monitoring of pathophysiological status in female reproductive system disorders.Identification of Candidate Serum Biomarkers for Schistosoma mansoni Infected Mice Using Multiple Proteomic Platforms.A novel "reactomics" approach for cancer diagnosticsMacrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areasOvarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers.Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometryBiomarkers of Helicobacter pylori-associated gastric cancer.Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down/bottom-up integrated approaches.Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma.
P2860
Q26751068-88DAD402-F74C-475C-B649-AF3A3E329C16Q26778026-22F20199-9E6C-47AA-B40F-C21E3949ACDCQ33844233-18CD4824-3403-46CE-9AAF-9A3B83EA687AQ34015109-5D2D541C-19B3-4B10-9C72-8D31C1BA883EQ34358608-F535F95D-F43A-404D-8742-A3EB98CCDC56Q34555445-1A9CE7C1-8D2F-42F7-BD49-E88BE8578472Q34986725-BEF9C154-048C-40DA-83BA-989C8528A013Q36006654-6778987B-4E7D-4570-AEF8-74E0AF787580Q36067925-16E774AC-DACD-488E-9E96-493708C8BAE0Q36385267-2612E2DD-5E44-4CC5-A192-9F8ADE6C2F29Q36556482-E7E280A8-2D86-4D78-8C7D-200920CBED19Q37174708-08C84A44-D74B-48BC-BC30-E39D14691AD2Q37591506-A88D01A2-F214-41CE-A3D2-CCB2B0BD2EB6Q44190698-833EB112-9836-49E9-A18A-450CE67998DAQ51064892-DBF72EC6-20B5-4451-B399-6E7418CC5A66
P2860
Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@ast
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@en
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@nl
type
label
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@ast
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@en
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@nl
prefLabel
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@ast
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@en
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@nl
P2093
P2860
P3181
P1433
P1476
Serum apolipoproteins C-I and ...... d immuno-based clinical assays
@en
P2093
Aleksandra Kugel
Angel Porgador
Dror Harats
Eitan Rubin
Herve Boissin
Jonathan Bones
Mark M Karpasas
Meital Cohen
Michael Welt
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0014540
P407
P50
P577
2011-01-18T00:00:00Z